Phase II clinical trial of high-dose recombinant human tumor necrosis factor.
about
Targeting the tumor vasculature to enhance T cell activityTumor necrosis factor-mediated interactions between inflammatory response and tumor vascular bed.Cardiomyopathy associated with high-dose interleukin-2 therapy.Systemic use of tumor necrosis factor alpha as an anticancer agentRole of isolated limb perfusion with recombinant human tumor necrosis factor α and melphalan in locally advanced extremity soft tissue sarcoma.FOLFIRI plus dulanermin (rhApo2L/TRAIL) in a patient with BRAF-mutant metastatic colon cancer.Tumor-targeted gene delivery of tumor necrosis factor-alpha induces tumor necrosis and tumor regression without systemic toxicity.
P2860
Q27026329-DA4FBCA8-DAFE-4E19-91E7-C9CCE9A925FEQ33325343-E9064049-63B6-4552-B52F-4BE5E2F31C8BQ33559591-41922770-789B-46F1-8E91-FFCC9614C80DQ35640180-A507EB2D-F292-4F6F-BAFB-B673AEE1C5C1Q38838678-F9362731-6BC9-4FA5-8496-7F7E3F7C589BQ42203684-0A20862C-8EE9-41C5-8683-EE0B8D8957B1Q45888026-4FC7433D-26CF-4571-8070-4A6DCF56EEAE
P2860
Phase II clinical trial of high-dose recombinant human tumor necrosis factor.
description
1989 nî lūn-bûn
@nan
1989年の論文
@ja
1989年学术文章
@wuu
1989年学术文章
@zh-cn
1989年学术文章
@zh-hans
1989年学术文章
@zh-my
1989年学术文章
@zh-sg
1989年學術文章
@yue
1989年學術文章
@zh
1989年學術文章
@zh-hant
name
Phase II clinical trial of high-dose recombinant human tumor necrosis factor.
@en
type
label
Phase II clinical trial of high-dose recombinant human tumor necrosis factor.
@en
prefLabel
Phase II clinical trial of high-dose recombinant human tumor necrosis factor.
@en
P2093
P356
P1476
Phase II clinical trial of high-dose recombinant human tumor necrosis factor.
@en
P2093
P2888
P304
P356
10.1007/BF00257449
P577
1989-01-01T00:00:00Z
P6179
1010802251